John F. Seymour, MBBS, PhD

In this interview, we discuss the results of the phase III MURANO trial, which tested the combination of venetoclax with rituximab in relapsed/refractory CLL.

Although the prospect is tempting, we do not believe there are sufficient grounds at this time to abandon bone marrow biopsy in patients with lymphoma. It still provides robust prognostic information, and in the majority of patients it remains an indispensable staging tool.

Biologic therapy for cancer may be defined as the use of compounds, or their derivatives, that can be found within the body to treat malignancy. The recent era of biologic therapy began with the identification and isolation of interferon (IFN)[1] and has been expanded with interleukin-2 (IL-2, aldesleukin [Proleukin]), the hematopoietic growth factors, and the retinoids.